243 related articles for article (PubMed ID: 15123247)
41. A novel computational analysis of ligand-induced conformational changes in the ATP binding sites of cyclin dependent kinases.
Subramanian J; Sharma S; B-Rao C
J Med Chem; 2006 Sep; 49(18):5434-41. PubMed ID: 16942017
[TBL] [Abstract][Full Text] [Related]
42. Rapid evolution of 6-phenylpurine inhibitors of protein kinase B through structure-based design.
Donald A; McHardy T; Rowlands MG; Hunter LJ; Davies TG; Berdini V; Boyle RG; Aherne GW; Garrett MD; Collins I
J Med Chem; 2007 May; 50(10):2289-92. PubMed ID: 17451235
[TBL] [Abstract][Full Text] [Related]
43. 2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity.
Wang S; Meades C; Wood G; Osnowski A; Anderson S; Yuill R; Thomas M; Mezna M; Jackson W; Midgley C; Griffiths G; Fleming I; Green S; McNae I; Wu SY; McInnes C; Zheleva D; Walkinshaw MD; Fischer PM
J Med Chem; 2004 Mar; 47(7):1662-75. PubMed ID: 15027857
[TBL] [Abstract][Full Text] [Related]
44. Thiazolo[5,4-f]quinazolin-9-ones, inhibitors of glycogen synthase kinase-3.
Testard A; Logé C; Léger B; Robert JM; Lozach O; Blairvacq M; Meijer L; Thiéry V; Besson T
Bioorg Med Chem Lett; 2006 Jul; 16(13):3419-23. PubMed ID: 16644220
[TBL] [Abstract][Full Text] [Related]
45. Discovery of novel thieno[2,3-d]pyrimidin-4-yl hydrazone-based inhibitors of cyclin D1-CDK4: synthesis, biological evaluation and structure-activity relationships. Part 2.
Horiuchi T; Nagata M; Kitagawa M; Akahane K; Uoto K
Bioorg Med Chem; 2009 Dec; 17(23):7850-60. PubMed ID: 19889545
[TBL] [Abstract][Full Text] [Related]
46. Design and synthesis of novel amide AKT1 inhibitors with selectivity over CDK2.
Ashton KS; St Jean DJ; Poon SF; Lee MR; Allen JG; Zhang S; Lofgren JA; Zhang X; Fotsch C; Hungate R
Bioorg Med Chem Lett; 2011 Sep; 21(18):5191-6. PubMed ID: 21824779
[TBL] [Abstract][Full Text] [Related]
47. Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors.
Dwyer MP; Paruch K; Alvarez C; Doll RJ; Keertikar K; Duca J; Fischmann TO; Hruza A; Madison V; Lees E; Parry D; Seghezzi W; Sgambellone N; Shanahan F; Wiswell D; Guzi TJ
Bioorg Med Chem Lett; 2007 Nov; 17(22):6216-9. PubMed ID: 17904366
[TBL] [Abstract][Full Text] [Related]
48. Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 2: identification and optimisation of substituted 2,4-bis anilino pyrimidines.
Breault GA; Ellston RP; Green S; James SR; Jewsbury PJ; Midgley CJ; Pauptit RA; Minshull CA; Tucker JA; Pease JE
Bioorg Med Chem Lett; 2003 Sep; 13(18):2961-6. PubMed ID: 12941312
[TBL] [Abstract][Full Text] [Related]
49. Structural basis for the inhibition of Aurora A kinase by a novel class of high affinity disubstituted pyrimidine inhibitors.
Tari LW; Hoffman ID; Bensen DC; Hunter MJ; Nix J; Nelson KJ; McRee DE; Swanson RV
Bioorg Med Chem Lett; 2007 Feb; 17(3):688-91. PubMed ID: 17157005
[TBL] [Abstract][Full Text] [Related]
50. Mechanism-based design of a protein kinase inhibitor.
Parang K; Till JH; Ablooglu AJ; Kohanski RA; Hubbard SR; Cole PA
Nat Struct Biol; 2001 Jan; 8(1):37-41. PubMed ID: 11135668
[TBL] [Abstract][Full Text] [Related]
51. Discovery and characterization of a substrate selective p38alpha inhibitor.
Davidson W; Frego L; Peet GW; Kroe RR; Labadia ME; Lukas SM; Snow RJ; Jakes S; Grygon CA; Pargellis C; Werneburg BG
Biochemistry; 2004 Sep; 43(37):11658-71. PubMed ID: 15362850
[TBL] [Abstract][Full Text] [Related]
52. Structure-driven HtL: design and synthesis of novel aminoindazole inhibitors of c-Jun N-terminal kinase activity.
Stocks MJ; Barber S; Ford R; Leroux F; St-Gallay S; Teague S; Xue Y
Bioorg Med Chem Lett; 2005 Jul; 15(14):3459-62. PubMed ID: 15950471
[TBL] [Abstract][Full Text] [Related]
53. Structural and functional analysis of cyclin D1 reveals p27 and substrate inhibitor binding requirements.
Liu S; Bolger JK; Kirkland LO; Premnath PN; McInnes C
ACS Chem Biol; 2010 Dec; 5(12):1169-82. PubMed ID: 20843055
[TBL] [Abstract][Full Text] [Related]
54. Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases.
Polychronopoulos P; Magiatis P; Skaltsounis AL; Myrianthopoulos V; Mikros E; Tarricone A; Musacchio A; Roe SM; Pearl L; Leost M; Greengard P; Meijer L
J Med Chem; 2004 Feb; 47(4):935-46. PubMed ID: 14761195
[TBL] [Abstract][Full Text] [Related]
55. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6.
Toogood PL; Harvey PJ; Repine JT; Sheehan DJ; VanderWel SN; Zhou H; Keller PR; McNamara DJ; Sherry D; Zhu T; Brodfuehrer J; Choi C; Barvian MR; Fry DW
J Med Chem; 2005 Apr; 48(7):2388-406. PubMed ID: 15801831
[TBL] [Abstract][Full Text] [Related]
56. Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 1: identification and optimisation of substituted 4,6-bis anilino pyrimidines.
Beattie JF; Breault GA; Ellston RP; Green S; Jewsbury PJ; Midgley CJ; Naven RT; Minshull CA; Pauptit RA; Tucker JA; Pease JE
Bioorg Med Chem Lett; 2003 Sep; 13(18):2955-60. PubMed ID: 12941311
[TBL] [Abstract][Full Text] [Related]
57. New potential inhibitors of cyclin-dependent kinase 4: design and synthesis of pyrido[2,3-d]pyrimidine derivatives under microwave irradiation.
Tu S; Zhang J; Zhu X; Xu J; Zhang Y; Wang Q; Jia R; Jiang B; Zhang J
Bioorg Med Chem Lett; 2006 Jul; 16(13):3578-81. PubMed ID: 16621547
[TBL] [Abstract][Full Text] [Related]
58. Structure-based design of a new class of highly selective aminoimidazo[1,2-a]pyridine-based inhibitors of cyclin dependent kinases.
Hamdouchi C; Zhong B; Mendoza J; Collins E; Jaramillo C; De Diego JE; Robertson D; Spencer CD; Anderson BD; Watkins SA; Zhang F; Brooks HB
Bioorg Med Chem Lett; 2005 Apr; 15(7):1943-7. PubMed ID: 15780638
[TBL] [Abstract][Full Text] [Related]
59. Fascaplysin-inspired diindolyls as selective inhibitors of CDK4/cyclin D1.
Aubry C; Wilson AJ; Emmerson D; Murphy E; Chan YY; Dickens MP; García MD; Jenkins PR; Mahale S; Chaudhuri B
Bioorg Med Chem; 2009 Aug; 17(16):6073-84. PubMed ID: 19632122
[TBL] [Abstract][Full Text] [Related]
60. Inhibition of cancer cell growth by cyclin dependent kinase 4 inhibitors synthesized based on the structure of fascaplysin.
Mahale S; Aubry C; Jenkins PR; Maréchal JD; Sutcliffe MJ; Chaudhuri B
Bioorg Chem; 2006 Oct; 34(5):287-97. PubMed ID: 16904725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
